NCT Number: NCT00090298
Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)
A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–69 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
The duration of treatment is 6 weeks.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Men and women aged 18 to 69 years, with elevated cholesterol levels may be eligible to participate in a research study to assess the efficacy and safety of two marketed drugs.
Treatment and study plan
Comparator: Rosuvastatin
DrugPrimary outcomes
-
LDL-C lowering efficacy after 6 weeks.
Secondary outcomes
-
Safety;changes in TC, non-HDL-C, TG, HDL-C, Apo B, LDL-C/HCL-C ratio.
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Organon and Co
Industry
Registry information
Official study title
A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia
Important dates
- Study start
- 2004
- Primary completion
- 2004
- Study completion
- 2004
- First posted
- Aug 30, 2004
- Registry last updated
- Aug 15, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
NCT05362903
Arterial Occlusive Diseases, Arteriosclerosis
Freudenstadt, Baden-Wurttemberg, Germany
View Trial DetailsA Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
NCT05952856
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Daphne, Alabama, United States
View Trial DetailsLipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
NCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial DetailsFunctional Cereal Products and Contribution to the Regulation of Metabolism and Obesity-induced Chronic Low-grade Inflammation.
NCT06822621
Body Weight, Dyslipidemias
Athens, Attica, Greece
View Trial Details